Use of Platelet-rich Plasma in Second-degree Superficial Burns

Overview

Platelet-rich plasma (PRP) obtained from the patient's blood has been used in many clinical and experimental studies, primarily wound healing, and successful results have been achieved. PRP has been used in various studies in the treatment of burn wounds, and positive results have been obtained. However, investigators did not find any study or publication about the use of PRP in second-degree superficial burns in our screening. Investigators planned a prospective randomized controlled and multicenter study to investigate the positive effects of PRP in the treatment of second-degree superficial burn.

Full Title of Study: “Use of Platelet-Rich Plasma in Second-Degree Superficial Burns; Multicentric Prospective Randomized Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: September 30, 2020

Detailed Description

The study was planned to be performed between 01.03.2020 and 01.04.2020 in Health Sciences University Konya Training and Research Hospital Burn Unit and Health Sciences University Mogadishu-Somalia Recep Tayyip Erdogan Training and Research Hospital General Surgery Clinics. Patients hospitalized with a second degree superficial burn and treated with PRP will be included in the study. Primary purpose: To investigate the effectiveness of platelet-rich plasma in burn treatment Secondary purpose: None. Platelet-rich plasma has recently been used in medicine for the treatment of various diseases. In our study, patients hospitalized in our clinic with the diagnosis of second-degree superficial burn were randomized and divided into two equal groups. It was planned to treat the first group with PRP, and the second group to be treated with a conventional method of dressing containing silver sulfadiazine cream. Patients will be given clear and understandable information about the study. Patients who agree to participate in the study will receive a consent form explaining that they have participated in the study voluntarily. The secretary will do randomization with the help of a computer program. A note stating which group the patient is in will be placed in a closed envelope. A randomization envelope will be opened in each patient before starting treatment. The primary endpoint of the study was determined as the day when the burn was epithelialized 100%. Secondary endpoints are the deepening of the wound and the application of other treatment modalities, including surgery, or an infection in the burn area. In our power analysis, investigators found the number of patients as 80% power and 28 patients with an alpha value of 0.05. Assuming that 10% of patients will be excluded during the study, investigators calculated that a total of 31 patients should be studied.

Interventions

  • Procedure: PRP group
    • Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
  • Procedure: conventional treatment group
    • The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.

Arms, Groups and Cohorts

  • Active Comparator: PRP group
    • Second-degree superficial burn group treated with PRP
  • Active Comparator: conventional treatment group
    • second-degree superficial burn group treated with cream containing silver sulfadiazine

Clinical Trial Outcome Measures

Primary Measures

  • PRP use in second degree burn treatment
    • Time Frame: 01.03.2020-30.04.2020
    • In the study, the effectiveness of burn treatment in both groups will be determined by recording the day of epithelialization.

Participating in This Clinical Trial

Inclusion Criteria

  • having a second-degree superficial burn – To be over the age of 16. Exclusion Criteria:

  • Patients under 16 – Patients with a burn of more than 30% of the total body surface area. – Patients with additional trauma with a burn wound. – Diabetes mellitus, renal failure requiring dialysis and having decompensated heart disease – Being pregnant and breastfeeding. – The patient does not want to participate in the study.

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Konya Training and Research Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Alpaslan ┼×ahin, Principal Investigator – Konya Training and Research Hospital

References

Venter NG, Marques RG, Santos JS, Monte-Alto-Costa A. Use of platelet-rich plasma in deep second- and third-degree burns. Burns. 2016 Jun;42(4):807-14. doi: 10.1016/j.burns.2016.01.002. Epub 2016 Jan 25.

Grippaudo FR, Carini L, Baldini R. Procutase versus 1% silver sulphadiazine in the treatment of minor burns. Burns. 2010 Sep;36(6):871-5. doi: 10.1016/j.burns.2009.10.021. Epub 2010 Jan 15.

Zheng W, Zhao DL, Zhao YQ, Li ZY. Effectiveness of platelet rich plasma in burn wound healing: a systematic review and meta-analysis. J Dermatolog Treat. 2020 Feb 21:1-7. doi: 10.1080/09546634.2020.1729949. [Epub ahead of print]

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.